In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to sl-401, an interleukin-3 receptor targeted biologic agent

Haematologica

Volumn 100, Issue 2, 2015, Pages 223-230

  Angelot Delettre, Fanny ^a,b,c,d   Roggy, Anne ^a,b,c,d   Frankel, Arthur E ^e   Lamarthee, Baptiste ^a,b,c,d   Seilles, Estelle ^a,b,c,d   Biichle, Sabeha ^a,b,c,d   Royer, Bernard ^a,b,c,d,f   Deconinck, Eric ^a,b,c,d,f   Rowinsky, Eric K ^g   Brooks, Christopher ^g   Bardet, Valerie ^h   Benet, Blandine ⁱ   Bennani, Hind ^j   Benseddik, Zehaira ^k   Debliquis, Agathe ^k   Lusina, Daniel ^l   Roussel, Mikael ^m   Solly, Françoise ⁿ   Ticchioni, Michel ^o   Saas, Philippe ^a,b,c,d,f   Garnache Ottou, Francine ^a,b,c,d   more..

^a INSERM   (France)

^b UNIVERSITÉ BOURGOGNE FRANCHE COMTÉ   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d LabEX LipSTIC   (France)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY HOSPITAL OF BESANÇON   (France)

^g Stemline Therapeutics Inc   (United States)

^h Institut Cochin   (France)

ⁱ Centre Hospitalier Regional Metz Thionville   (France)

^j INSTITUT CURIE   (France)

^k CH Chartres ^*  (France)

^l AVICENNE HOSPITAL   (France)

^m RENNES UNIVERSITY HOSPITAL   (France)

ⁿ UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^o UNIVERSITÉ CÔTE D'AZUR   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD123 ANTIGEN; CD131 ANTIGEN; SL 401; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; BLOOD CELL COUNT; BONE MARROW STROMA CELL; CANCER CELL CULTURE; CELL ISOLATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY ASSAY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; IMMUNOPHENOTYPING; KARYOTYPING; MOUSE; MTT ASSAY; NEOPLASM; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

EID: 84964299203     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.111740     Document Type: Article

References (42)

1. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97(10):3210-3217.
2. Swerdlow SH, Campo E, Harris NL, et al. World Health Organisation Classification of Tumors. 4th ed. Lyon; 2008.
3. Jegalian AG, Buxbaum NP, Facchetti F, et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica. 2010;95(11):1873-1879.
4. Sakashita K, Saito S, Yanagisawa R, et al. Usefulness of allogeneic hematopoietic stem cell transplantation in first complete remission for pediatric blastic plasmacytoid dendritic cell neoplasm with skin involvement: a case report and review of literature. Pediatr Blood Cancer. 2013;60(11): E140-142.
5. Julia F, Petrella T, Beylot-Barry M, et al. Blastic plasmacytoid dentritic cell neoplasm: clinical features in 90 patients. Br J Dermatol. 2013;169(3):579-586.
6. Petrella T, Meijer CJ, Dalac S, et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blas-tic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol. 2004;122(2):307-313.
7. Angelot-Delettre F, Biichle S, Ferrand C, et al. Intracytoplasmic detection of TCL1--but not ILT7-by flow cytometry is useful for blastic plasmacytoid dendritic cell leukemia diagnosis. Cytometry A. 2012;81(8):718-724.
8. Garnache-Ottou F, Feuillard J, Ferrand C, et al. Extended diagnostic criteria for plasma-cytoid dendritic cell leukaemia. Br J Haematol. 2009;145(5):624-636.
9. Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 2008;111(7):3778-3792.
10. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol. 2005;123(5): 662-675.
11. Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol. 2009;162(1):74-79.
12. Dietrich S, Andrulis M, Hegenbart U, et al. Blastic plasmacytoid dendritic cell neopla-sia (BPDC) in elderly patients: results of atreatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant. 2011;17(8):1250-1254.
13. Roos-Weil D, Dietrich S, Boumendil A, et al. Stem cell transplantation can provide durable disease control in blastic plasmacy-toid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2013;121(3):440-446.
14. Gilis L, Lebras L, Bouafia-Sauvy F, et al. Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm. Leuk Lymphoma. 2012;53(8):1633-1637.
15. Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239-246.
16. Piccaluga PP, Paolini S, Sapienza MR, Pileri SA. Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? Expert Rev Hematol. 2012;5 (4):353-355.
17. Ramanathan M, Cerny J, Yu H, Woda BA, Nath R. A combination treatment approach and cord blood stem cell transplant for blas-tic plasmacytoid dendritic cell neoplasm. Haematologica. 2013;98(3):e36.
18. Blalock WL, Weinstein-Oppenheimer C, et al. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia. 1999;13(8):1109-1166.
19. Miyajima A, Kitamura T, Harada N, Yokota T, Arai K. Cytokine receptors and signal transduction. Annu Rev Immunol. 1992;10:295-331.
20. Frankel AE, Ramage J, Kiser M, Alexander R, Kucera G, Miller MS. Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Eng. 2000;13(8):575-581.
21. Rapoport AP, Luhowskyj S, Doshi P, DiPersio JF. Mutational analysis of the alpha subunit of the human interleukin-3 receptor. Blood. 1996;87(1):112-122.
22. Kreitman RJ. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs. 2009;23(1):1-13.
23. Frankel A, Liu JS, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodyspla-sia. Leuk Lymphoma. 2008;49(3):543-553.
24. Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to the interleukin-3 receptor, in patients with blas-tic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385-392.
25. Perruche S, Kleinclauss F, Lienard A, Robinet E, Tiberghien P, Saas P. A single-platform approach using flow cytometry and microbeads to evaluate immune recon-stitution in mice after bone marrow transplantation. J Immunol Methods. 2004;294(1-2):53-66.
26. Frankel AE, McCubrey JA, Miller MS, et al. Diphtheria toxin fused to human inter-leukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia. 2000;14(4):576-585.
27. Black JH, McCubrey JA, Willingham MC, Ramage J, Hogge DE, Frankel AE. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia. 2003;17(1):155-159.
28. Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, Hogge DE. A diphtheria toxin-interleukin 3 fusion protein is cyto-toxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res. 2002;62(6):1730-1736.
29. Alexander RL, Ramage J, Kucera GL, Caligiuri MA, Frankel AE. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res. 2001;25(10):875-881.
30. Hogge DE, Yalcintepe L, Wong SH, Gerhard B, Frankel AE. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res. 2006;12(4):1284-1291.
31. Su Y, Li SY, Ghosh S, Ortiz J, Hogge DE, Frankel AE. Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials. Biologicals. 2010;38(1):144-149.
32. Angelot-Delettre F, Frankel A, Liu J, et al. The IL-3Ra-targeted drug SL-401 selective-ly kills blastic plasmacytoid dendritic cell neoplasm cells. Blood. 2011;118:2588.
33. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The enigmatic plas-macytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med. 1997;185(6):1101-1111.
34. Ben Amor R, Hicheri Y, Pautas C, et al. Successful non-myeloablative allogeneic HLA-identical stem cell transplantation for CD4/CD56 positive acute leukemia. Transplantation. 2007;84(8):1066-1067.
35. Fontaine J, Thomas L, Balme B, et al. Haematodermic CD4+CD56+ neoplasm: complete remission after methotrexate-asparaginase treatment. Clin Exp Dermatol. 2009;34(5):e43-45.
36. Gruson B, Vaida I, Merlusca L, et al. L-asparaginase with methotrexate and dex-amethasone is an effective treatment combination in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol. 2013;163(4): 543-545.
37. Leitenberger JJ, Berthelot CN, Polder KD, et al. CD4+ CD56+ hematodermic/plasma-cytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol. 2008;58(3):480-484.
38. Narita M, Kuroha T, Watanabe N, et al. Plasmacytoid dendritic cell leukemia with potent antigen-presenting ability. Acta Haematol. 2008;120(2):91-99.
39. Agliano A, Martin-Padura I, Marighetti P, et al. Therapeutic effect of lenalidomide in a novel xenograft mouse model of human blastic NK cell lymphoma/blastic plasma-cytoid dendritic cell neoplasm. Clin Cancer Res. 2011;17(19):6163-6173.
40. Menezes J, Acquadro F, Wiseman M, et al. Exome sequencing reveals novel and recurrent mutations with clinical impact in blas-tic plasmacytoid dendritic cell neoplasm. Leukemia. 2014;28(4):823-829.
41. Sapienza MR, Fuligni F, Agostinelli C, et al. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia. 2014;28(8):1606-1616.
42. Hertler AA, Schlossman DM, Borowitz MJ, Poplack DG, Frankel AE. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol Immunother. 1989;28(1):59-66.